Novartis: Higher Guidance, Now A Buy [Seeking Alpha]
MorphoSys AG - American Depositary Shares (MOR)
Company Research
Source: Seeking Alpha
Despite a negative FX, the company reported solid 2023 financial results and increased its dividend per share. There is a strategic rationale for acquiring MorphoSys AG. NVS had raised its outlook for three quarters in a row. We have now moved our rating to buy. Following the Sandoz spin-off and Alcon sale, Novartis ( NYSE: NVS OTCPK:NVSEF ) has completed a big step in its transformation into a pure-play in innovative medicines ( Fig 1 Fig 1 Post Investor Day, we decided to raise our EPS forecast to CHF 7, arriving at a valuation of CHF 101.5 per share. Here at the Lab, we had mixed feelings about the company. On the one hand, Novartis is a quality business with a solid balance sheet and a strong R&D franchise. During the 2023 results, the CEO explained how Novartis "delivered ten positive Ph3 readouts on assets with significant sales potential" (Fig 3) For this reason, the company increased its sales growth driver expectation of 5% until 2028 with a margin above 40% by 202
Show less
Read more
Impact Snapshot
Event Time:
MOR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MOR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MOR alerts
High impacting MorphoSys AG - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
MOR
News
- MorphoSys: Hold Rating Until The Novartis Deal Closes [Seeking Alpha]Seeking Alpha
- MorphoSys reports Q1 results [Seeking Alpha]Seeking Alpha
- European Stocks Steady as Philips Soars, Deutsche Bank Drops [BNN Bloomberg (Canada)]BNN Bloomberg
- MorphoSys AG Reports First Quarter 2024 Financial Results [Yahoo! Finance]Yahoo! Finance
- MorphoSys AG Reports First Quarter 2024 Financial ResultsBusiness Wire